临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Ivermectin (MK-933)
CAS号:70288-86-7
分子式: C48H74O14 分子量: 875.09
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Scabies
研究机构: University of Oxford; Fundação de Medicina Tropical Dr. Heitor Vieira Dourado; Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta (FUAM); University of Basel; ClinSearch
研发日期: October 1 2024
研发阶段: Phase 2
Ivermectin (MK-933, IVM) is a glutamate-gated chloride channel (GluCls) activator, used as a broad-spectrum antiparasitic drug. Ivermectin (MK-933, IVM) is a specific positive allosteric effector of P2X4 and α7 nicotinic acetylcholine receptors (nAChRs). Ivermectin has potent antiviral activity towards both HIV-1 and dengue virus. Ivermectin induces autophagy through the AKT/mTOR signaling pathway and mitophagy.
Glutathione
中文名称:谷胱甘肽/5-L-谷氨酰-L-半胱氨酰甘氨酸
CAS号:70-18-8
分子式: C10H17N3O6S 分子量: 307.32
产品形式: free base
研发状态: Not yet recruiting
研发用途: Diabetes Mellitus Type 2; Insulin Resistance
研究机构: Kerman Medical University; Afzalipour Hospital
研发日期: June 14 2024
研发阶段: Phase 4
Glutathione (Isethion, Tathion, L-Glutathione reduced, GSH; γ-L-Glutamyl-L-cysteinyl-glycine) acts as an antioxidant, a free radical scavenger and a detoxifying agent. It is a tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) present in most mammalian tissue.
Pimonidazole
中文名称: 哌莫硝唑
CAS号:70132-50-2
分子式: C11H18N4O3 分子量: 254.29
产品形式: Free Base
研发状态: Withdrawn
研发用途: Pancreatic Cancer; Resectable Pancreatic Cancer
研究机构: H. Lee Moffitt Cancer Center and Research Institute; Varian Medical Systems
研发日期: April 1 2021
研发阶段: Early Phase 1
Pimonidazole (Ro 03-8799) is a novel hypoxia marker used for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.
Galunisertib (LY2157299)
中文名称:4-[5,6-二氢-2-(6-甲基-2-吡啶基)-4H-吡咯并[1,2-b]吡唑-3-基]-6-喹啉甲酰胺
CAS号:700874-72-2
分子式: C22H19N5O 分子量: 369.42
产品形式: free base
研发状态: Unknown status
研发用途: Colorectal Cancer Metastatic
研究机构: The Netherlands Cancer Institute; Vall d''Hebron Institute of Oncology; Agendia; European Organisation for Research and Treatment of Cancer - EORTC; Azienda Ospedaliera Niguarda Cà Granda; Fundación para la Investigación del Hospital Clínico de Valencia; University of Campania Luigi Vanvitelli; University of Turin Italy; Eli Lilly and Company; Catalan Institute of Health; Universitaire Ziekenhuizen KU Leuven
研发日期: Feb-20
研发阶段: Phase 1 : Phase 2
Galunisertib (LY2157299) is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM in a cell-free assay. Phase 2/3.
Rilpivirine Hydrochloride
中文名称:4-{[4-({4-[(E)-2-氰基乙烯基]-2,6-二甲基苯基}氨基)-2-嘧啶基]氨基}苯甲腈盐酸盐(1:1)
CAS号:700361-47-3
分子式: C22H18N6.ClH 分子量: 402.88
产品形式: hydrochloride
研发状态: Completed
研发用途: Healthy
研究机构: Janssen Pharmaceutical K.K.
研发日期: Mar-13
研发阶段: Phase 4
Rilpivirine (TMC278), is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.
Terazosin HCl Dihydrate
中文名称:盐酸特拉唑嗪二水物
CAS号:70024-40-7
分子式: C19H25N5O4.HCl.2H2O 分子量: 459.92
产品形式: HCl & Dihydrate
研发状态: Not yet recruiting
研发用途: Dementia With Lewy Bodies
研究机构: Qiang Zhang; University of Iowa
研发日期: Oct-24
研发阶段: Phase 1 : Phase 2
Terazosin HCl is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
